Tolerx

Tolerx Develops Novel Therapies Focused on Modulating T-Cell Activity for the Treatment of Autoimmune Diseases, Diabetes, and Cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for the treatment of type 1 diabetes; MTRX1011A, an anti-CD4 antibody for autoimmune indications; and TRX518 and TRX385, preclinical candidates aimed at optimizing immune responses for the treatment of cancer and chronic viral diseases.